Clinical trials: Zika
Zika, Influenza
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
Background: The Laboratory of Infectious Diseases (LID) Clinical Studies Unit (CSU) enrolls healthy volunteers into clinical studies to study infectious diseases. Viruses can be highly infectious and contagious.
- Trial name
- NCT01386424
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Zika Virus, Congenital Zika Syndrome
Neurodevelopmental Outcomes in ZIKV-Exposed Children
In this study the investigators will follow the neurodevelopmental outcome of children with in utero ZIKV exposure who do not have microcephaly or severe abnormalities consistent with Congenital Zika Syndrome.
- Conditions
- Zika Virus, Congenital Zika Syndrome, Congenital Infection, Child Development
- Trial name
- NCT04398901
- Testing
- Neurodevelopmental assessments
- Where
- 2 sites in United States, Colombia
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Children's National Research Institute
Zika Virus Infection, Adherence, Patient
Adherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico
Given the magnitude of the epidemic in Puerto Rico, congenital Zika virus infection may have devastating complications to a significant population of children, also affecting families and society at large.
- Trial name
- NCT05041439
- Testing
- Community Health Worker
- Where
- Puerto Rico
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Arbovirus Infections
The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
International travel has increased dramatically in recent years. Vector-borne pathologies such as malaria and arboviruses are common etiologies of post-travel fever, which are prevalent in similar geographical areas (tropical and…
- Trial name
- NCT06651372
- Testing
- The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Zika Virus, Dengue Virus
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Background: Zika virus is mostly passed on by the bite of an infected mosquito. It usually causes mild illness. But in pregnant women it can cause serious birth defects to the baby.
- Conditions
- Zika Virus, Dengue Virus, Chikungunya Virus Infections
- Trial name
- NCT02794181
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Zika Virus, Pregnancy Related
ZIKAlliance Pregnant Women Cohort
The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations.
- Trial name
- ZIKAlliancePW (NCT03188731)
- Where
- 14 sites in Bolivia, Brazil and 5 more
- Volunteers
- 3,852 people, healthy volunteers welcome
- Sponsor
- University of Heidelberg Medical Center
HIV Infections, Zika Virus Infection
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
This study will estimate the cumulative incidence of Zika infection at the end of the first epidemic in the French West Indies in a sample of patients followed for HIV infection.
- Trial name
- ZIKAVIH (NCT03161444)
- Testing
- Biological sample collection
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 354 people
- Sponsor
- University Hospital Center of Martinique
Zika Virus Infection, Zika Virus Disease
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
Currently, there are no licensed therapeutics against Zika virus infection. Due to this unmet medical need, Zika Virus Immune Globulin (ZIKV-IG) is being developed as a therapeutic intervention against Zika virus infection.
- Trial name
- NCT03624946
- Testing
- Zika Virus Immune Globulin (ZIKV-IG)
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Zika Virus, Zika Virus Disease
Persistence of Zika Virus in Semen After Acute Infection
This is a prospective observational laboratory evaluation of the persistence rate of zika virus (ZIKV) infection in semen by real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), and assessment of ZIKV…
- Conditions
- Zika Virus, Zika Virus Disease, Virus Shedding, Transmission
- Trial name
- NCT02733796
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Treatment of Acute Zika Virus Infection
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients
Zika virus (ZIKV) infection is a new emerging arbovirus disease, caused by the same vector that transmits Dengue virus, Aedes aegypti.
- Trial name
- NCT03776695
- Testing
- Tyzivumab
- Where
- Singapore
- Sponsor
- Tychan Pte Ltd.
Zika Virus Infection
Safety and Immunogenicity of BBV121
To evaluate the safety, tolerability, and immunogenicity of two-doses of three-sequentially escalating cohort (2.5 µg, 5 µg and 10 µg) of BBV121 (purified inactivated adsorbed Zika virus vaccine) compared with Placebo (Alum).
- Trial name
- Zika (NCT04478656)
- Testing
- BBV121
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Zika Virus
Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
This is a phase 1 double-blind, placebo controlled trial designed to evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of…
- Trial name
- NCT03611946
- Testing
- Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Zika
Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale
Mosquito-borne diseases cause suffering for hundreds of millions of people and claim more than 700,000 lives yearly. Diseases such as dengue, Zika, and chikungunya cause symptoms similar to malaria and are endemic in many parts…
- Conditions
- Dengue, Zika, Chikungunya
- Trial name
- NCT06595745
- Testing
- Wolbachia induced incompatible mating, Standard traditional chemical mosquito control
- Where
- Mexico
- Volunteers
- 15,243 people, healthy volunteers welcome
- Sponsor
- Michigan State University
ZIKA VIRUS INFECTION, Child Development
Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
The recent increase in the number of cases of congenital microcephaly observed in Brazil is a reason of great concern. This increase occurred a few months after Zika virus (ZIKV) was introduced in the country, which was…
- Conditions
- ZIKA VIRUS INFECTION, Child Development, Microcephaly
- Trial name
- ZIKVIRUSIFF (NCT03255369)
- Testing
- Child exposed Zika virus proved
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Oswaldo Cruz Foundation
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Zika Virus Infection
Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)
This study is designed to investigate, at first, safety and tolerability of a novel liquid vaccine formulation named MV-ZIKA-RSP, in healthy adults aged 18 to 55 years
- Trial name
- MV-ZIKA-RSP (NCT04033068)
- Testing
- Two MV-ZIKA-RSP vaccinations (high dose), Two MV-ZIKA-RSP vaccination (low dose)
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Arbovirus Infections
Spatial Repellents for Arbovirus Control
Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly.
- Trial name
- NCT03553277
- Testing
- transfluthrin
- Where
- Peru
- Volunteers
- 18,240 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Zika Virus Disease
Zika Case Definition and Surveillance Study
This prospective, surveillance study will assess the operational Zika virus definition for use in future Zika purified inactivated virus (ZIKV) vaccine efficacy trials in order to identify Zika virus disease (ZVD) cases among the…
- Trial name
- NCT03158233
- Where
- 6 sites in Colombia, Honduras and 2 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Zika Virus Infection
Applying Wolbachia to Eliminate Dengue
This cluster randomised trial will evaluate the efficacy of Wolbachia-infected Aedes aegytpi mosquitoes in reducing dengue cases in Yogyakarta City, Indonesia
- Conditions
- Dengue, Zika Virus Infection, Chikungunya Fever
- Trial name
- AWED (NCT03055585)
- Testing
- Wolbachia-infected Aedes aegypti mosquitoes, standard practice dengue control
- Where
- Indonesia
- Volunteers
- 8,173 people
- Sponsor
- Gadjah Mada University
Dengue Fever
Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
Background: Some mosquitos carry viruses that can cause disease. Some examples are dengue and Zika. The mosquitos spread disease by biting people and infecting them with the virus.
- Trial name
- NCT03534245
- Where
- Cambodia
- Volunteers
- 775 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)